Alliance of Tech Founders Line up to Invest in the Next Generation of Global Innovators With $158m Series C Funding Round for Entrepreneur First
29.6.2022 09:00:00 EEST | Business Wire | Press release
Entrepreneur First (EF), a scaleup investor in early stage founder talent, has raised a $158m Series C funding round from a group of veteran technology founders, including Patrick and John Collison, Reid Hoffman, Taavet Hinrikus and Matt Mullenweg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005653/en/
Entrepreneur First co-founders Alice Bentinck and Matt Clifford (Photo: Business Wire)
Bucking the trend of mounting layoffs and diminishing venture capital volumes across the startup world, owing to fears of a looming recession, the host of successful entrepreneurs and founders are backing EF to unlock opportunities for a diverse set of new global founders.
EF’s impressive global roster of backers includes , John and Patrick Collison (co-founders of Stripe), Taavet Hinrikus (co-founder of Wise), Reid Hoffman (co-founder of LinkedIn), Matt Mullenweg (co-founder of Wordpress), Tom Blomfield (co-founder of Monzo and GoCardless), Nat Friedman (former CEO of Github), Sara Clemens (former COO of Twitch and Pandora), Matt Robinson (co-founder of Nested and GoCardless), Patrick O’Shaughnessy (Positive Sum), Demis Hassabis and Mustafa Suleyman (co-founders of Deepmind), Claire Hughes Johnson, Sten Tamkivi, Elad Gil and Lachy Groom.
Founded in 2011 by Matt Clifford and Alice Bentinck in London, EF now employs 120 around the world. It operates as an early-stage investor, helping talented people find co-founders to partner with ahead of launching startups.
“Talent is everywhere, but opportunity is not. The idea of taking strangers and helping them start robust and ambitious companies is no longer radical but essential to power the next stage of innovation,” said Matt Clifford, CEO and co-founder of Entrepreneur First.
“The whole EF thesis is finding individuals who otherwise might not start companies and then trying to accelerate their journey to success,” he said.
“EF is completely unique in the early-stage funding landscape. Our whole effort focuses on talent rather than typical venture capital deal flow. We don't try and win deals, we don't pick deals, we find great people. That brings big strengths. The ability to partner before there even is a company is both a relationship and an economic strength,” he added.
Reid Hoffman, co-founder of LinkedIn and Entrepreneur First board member said: “We are entering a new era for venture funding, with a new generation of global founders needing support to build iconic companies from scratch. I’m excited to be part of this world-class syndicate. We’re all passionate about the power of entrepreneurship to change people’s lives and to change the world. Entrepreneur First represents a new way for talented people to access that opportunity and a new way to build startup ecosystems outside Silicon Valley.”
Alice Bentinck, co-founder of Entrepreneur First, said: “As the value of EF’s portfolio companies passes $10bn, we feel we’re just getting started. We want EF to have a product to enable every ambitious individual to find their co-founder. EF is already one of the world’s great talent communities and with this new funding and these new investors, we’re looking forward to partnering with thousands of more exceptional founders in the coming years”
The cash -- raised as a funding round, rather than a ‘fund’ -- will be used to make investments into new startups as well as allow EF a capacity to experiment, and innovate on how best to fund the next generation of entrepreneurs by launching new products aimed at up-ending the typical venture capital model.
EF is also announcing today that the aggregate value of companies created through its platform now exceeds $10bn. Notable alumni include Tractable (the computer vision unicorn focused on the insurance industry, funded by Insight and Georgian Partners); Omnipresent (the employment platform for remote work, funded by Tencent and Kinnevik); Aztec Protocol (the private transaction protocol, funded by Paradigm); Cleo (the financial management app, funded by Balderton and EQT Ventures); and Permutive (the privacy-compliant advertising infrastructure platform, funded by Softbank).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005653/en/
Contact information
Ben Goldsmith
ben@goldsmithcomms.com
+44(0)7788295321
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom